Forced expiratory volume in one second: Not just a lung function test but a marker of premature death from all causes

European Respiratory Journal

Volumn 30, Issue 4, 2007, Pages 616-622

  Young, R P ^a,c   Hopkins, R ^b   Eaton, T E ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b GREEN LANE HOSPITAL   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Baseline risk; Chronic obstructive pulmonary disease; Epidemiology; Lung function; Premature death; Spirometry

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DISEASE MARKER; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CANCER; LUNG FUNCTION TEST; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING CESSATION; SPIROMETER; STROKE; ADULT; AGED; CARDIOVASCULAR DISEASE; LUNG DISEASE; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; RISK; RISK ASSESSMENT; SMOKING; SPIROMETRY; TIME;

ADULT; AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; RISK ASSESSMENT; SMOKING; SPIROMETRY; STROKE; TIME FACTORS;

EID: 37449001170     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00021707     Document Type: Review

References (55)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648.
2. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987; 106: 512-518.
3. Sin DD, Wu LL, Man SFP. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959.
4. Knot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary artery disease. JAMA 2003; 290: 898-904.
5. Stavem K, Aaser E, Sandvik L, et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J 2005; 25: 618-625.
6. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington County, Maryland. Am Rev Respir Dis 1989;140 S56-S63.
7. Olofson J, Skoogh BE, Bake B, Svärdsudd K. Mortality related to smoking habits, respiratory symptoms and lung function. Eur J Respir Dis 1987; 71: 69-76.
8. Truelsen T, Prescott E, Lange P, Schnohr P, Boysen G. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int J Epidemiol 2001; 30: 145-151.
9. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994; 309: 901-911.
10. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-715.
11. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679.
12. Mannino DM, Holguin F, Pavlin BI, Ferdinands JM. Risk factors for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis 2005; 9: 613-621.
13. Donaldson GC, Seemungal TAR, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003; 22: 931-936.
14. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quatitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977; 115: 195-205.
15. Dockery DW, Speizer FE, Ferris BG, Ware JH, Louis TA, Spiro A. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Respir Dis 1988; 137: 286-292.
16. Løkke A, Lange P, Scharling H, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-939.
17. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
18. Global Initiative for Chronic Obstructive Lung Diseases. www.goldcopd.com. Date last revised: 2006.
19. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627-643.
20. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Int Med 1986; 105: 503-507.
21. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Int Med 2003; 163: 1475-1480.
22. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005; 60: 570-575.
23. Bechtel JJ, Kelley WA, Coons TA, Klein MG, Slagel DD, Petty TL. Lung cancer detection in patients with airflow obstruction identified in a primary care outpatient practice. Chest 2005; 127: 1140-1145.
24. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
25. Petty TL. Are COPD and lung cancer two manifestations of the same disease? Chest 2005; 128: 1895-1897.
26. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
27. Boushey H, Enright P, Samet J. Spirometry for chronic obstructive pulmonary disease case finding in primary care? Am J Respir Crit Care Med 2005; 172: 1481-1482.
28. Górecka D, Bednarek M, Nowiński A, Puścińska E, Goljan-Geremek A, Zieliński J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923.
29. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869-873.
30. Wagena EJ, van der Meer RM, Ostelo RJ, Jacobs JE, van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004; 98: 805-815.
31. Rea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN, Psaty BM. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137: 494-500.
32. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer 2005; 103: 2154-2162.
33. West R, Sohal T. Catastrophic pathways to smoking cessation: findings from national survey. BMJ 2006; 332: 458-460.
34. Weinstein ND, Marcus SE, Moser RP. Smokers' unrealistic optimism about their risk. Tob Control 2005; 14: 55-59.
35. Manuel DG, Lim J, Tanuseputro P, et al. Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006; 332: 659-662.
36. Hunninghake DB. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 44-49.
37. Mancini GBJ, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
38. Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-283.
39. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131: 1006-1012.
40. Younis WG, Chbeir EA, Daher NN, Deraika TA, Kinasewitz GT, Kedissi JI. Statins protect smokers from lung disease. Chest 2006; 130: 180S.
41. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.
42. Mapel DW, Nelson LS, Lydick E, et al. Survival of COPD patients using Advair discus, inhaled corticosteroids and salmeterol individually, inhaled corticosteroids alone, or short acting bronchodilators alone. American Thoracic Society, San Diego, 2006; A110.
43. Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172: 460-464.
44. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ 2000; 321: 983-986.
45. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US Veterans. Chest 2007; 131: 1282-1288.
46. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006; 61: 729-734.
47. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172: 987-993.
48. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117: 1146-1161.
49. Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry work-shops. Chest 1999; 116: 416-423.
50. DeJong SR, Veltman RH. The effectiveness of a CNS-led community-based COPD screening and intervention program. Clin Nurse Spec 2004; 18: 72-79.
51. Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L., Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J 2006; 28: 945-952.
52. Yanbaeva DC, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF., Systemic effects of smoking. Chest 2007; 131: 1557-1566.
53. Pelkonen M, Tukiainen H, Tervahuata M, et al. Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax 2000; 55: 746-750.
54. Pelkonen M, Notkola IL, Tukiainen H, Tervahauta M, Tuomilehto J, Nissinen A. Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries study. Thorax 2001; 56: 703-707.
55. Krahn M, Chapman KR. Economic issues in the use of office spirometry for lung health assessment. Can Respir J 2003; 10: 320-326.